Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

NCT00189345 is registered in ClinicalTrials.gov with AGO Study Group as lead sponsor.

NCT NCT00189345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Lead sponsor
AGO Study Group
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
October 31, 2005
Enrollment
44
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, ovarian cancer, peritoneal neoplasms